Opinion in Israel

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Oxford GlycoSciences/Teva: identifying Israeli opportunities

The deal is important, since 10-15% of Gaucher disease patients live in Israel. While it goes against OGS' intended strategy of marketing Vevesca alone, the deviation will be beneficial in the long run. Israel will not be as strong a market for OGS' later compounds, and a large licensing payment at this stage will help it establish salesforces in the key pharma markets.

Published By Datamonitor
21 Nov 2001
CommentWire
CommentWire

Peptor: investigating additional indications in diabetes

DiaPep277 has already shown strong trial results for type I diabetes, which is in some ways similar to LADA. This makes the new investigation seem worthwhile. Approval would provide a new treatment option for an often-misdiagnosed subcategory of diabetic patients. It would also greatly increase the market potential of the drug, by allowing access to a much larger patient population.

Published By Datamonitor
15 Jan 2002
CommentWire
CommentWire

Mecca Cola: singing a different tune

Mecca Cola is in direct competition with Coca-cola, deliberately appealing to anti-US sentiments. This growing tendency for manufacturers to market themselves on a political positioning to take advantage of consumer concerns creates a loyal customer base that will not be easily swayed.

Published By Datamonitor
09 Jan 2003
CommentWire
CommentWire

Generic drugs: Ivax purchase puts Teva back on top

Teva has agreed to acquire rival generics maker Ivax for $7.4 billion. If the deal goes through, Teva will become the dominant force in the generics market again, pushing Novartis' Sandoz into second place. As the gap between these top two players and the rest of the field opens up, smaller companies may struggle to keep pace and could end up being takeover targets themselves.

Published By Datamonitor
26 Jul 2005
CommentWire
CommentWire

Teva: Copaxone on the up

Teva's biggest selling drug Copaxone has shown increased efficacy in multiple sclerosis in a high-dose phase II trial. This points to the possibility of a revival in Copaxone use, and increased competition for Biogen Idec and Elan's Tysabri if and when it is re-launched.

Published By Datamonitor
07 Apr 2006
CommentWire
CommentWire

Teva: FDA green light good news for Azilect

Teva Pharmaceutical has received FDA approval for Azilect as a treatment for Parkinson's disease, both as initial monotherapy in early Parkinson's patients and as an adjunct therapy to levodopa in moderate-to-advanced stages of the disease. While this is good news for Teva's second proprietary drug, its true potential may only be realized once long-term neuroprotection trials are completed.

Published By Datamonitor
19 May 2006
Expert View
Expert View

New food review: chocolate gets savory makeover

The savory tastes of consumers have been well catered for this month, with Productscan recording a selection of traditionally sweet products that have been given a savory makeover. These include bacon flavored chocolate and muffins with savory fillings, providing consumers with an increasing array of savory meal options.

Published By Datamonitor
24 Aug 2007
Expert View
Expert View

New drinks review: developing drinks for all occasions

The growing health trend has seen the release of an array of niche products, as a look at the latest launches on Productscan reveals. One such product is a new bottled water that has been created especially for diabetics, highlighting how drinks manufacturers attempt to get ahead of the competition by offering something different.

Published By Datamonitor
18 Jan 2008
Expert View
Expert View

New food review: targeting singles with limited edition foods

Meal options targeted at singles have been somewhat limited in the past, with most packaged foods catering for families or couples. A Norwegian store aims to change this by offering singles more choice, with a selection of limited edition meat cuts especially portioned for the singles market. As more people are living on their own, the singles market could become a bigger target in future.

Published By Datamonitor
20 Feb 2009
Expert View
Expert View

edge IPK and Earnix: seeking to help US carriers improve the customer relationship

Having established themselves in the European market, edge IPK and Earnix are expanding into the US property and casualty market. Both vendors have compelling offerings that should succeed in the US market, however, new regulations in the US insurance market and cost restrictions brought on by the current economic climate will not make it easy for either company.

Published By Datamonitor
10 Jul 2009

« | 1 | 2 | » »|

No help is available.